Cáceres-Lóriga Fidel Manuel, Pérez-López Horacio, Morlans-Hernández Karel, Facundo-Sánchez Humberto, Santos-Gracia José, Valiente-Mustelier Juan, Rodiles-Aldana Felipe, Marrero-Mirayaga Maria Acelia, Betancourt Blas Y, López-Saura Pedro
Institute of Cardiology and Cardiovascular Surgery, Havana, Cuba.
J Thromb Thrombolysis. 2006 Apr;21(2):185-90. doi: 10.1007/s11239-006-4969-y.
Valvular thrombosis is a serious complication in patients with prosthetic heart valves. Traditional treatment is emergency surgery, but thrombolysis provides a non invasive alternative. In this paper we evaluate the efficacy and safety of thrombolysis in prosthetic heart valve thrombosis.
Data of 68 patients diagnosed of prosthetic valve thrombosis, treated at the Institute of Cardiology and Cardiovascular Surgery, Havana during a 6-years period were analyzed. They received thrombolysis with a recombinant streptokinase infusion at 250,000 IU in 30 minutes followed by 100,000 IU/hour during 72 hours or less if the thrombosis resolved before. The evaluation was based on clinical and echocardiographic findings.
Affected sites were mitral (50 cases), tricuspid (9), and aortic (9). Mean time of prosthesis implantation was 6.8 years. The presentation form was generally heart failure (NYHA functional class III-IV) in 64 (94.1%) patients. Mean time interval between onset of symptoms and diagnosis was 10.6 days. There was total response to treatment in 58 (85.3%) patients, partial in 4 (5.9%) and failure in 6 (8.8%). Recombinant streptokinase overall dose was 5.1 x 10(6) IU and mean infusion time 50 hours. Major hemorrhagic complications were observed in two patients. Five embolic events occurred during thrombolysis. Four patients died. Rethrombosis was noted in 11 patients; 10 were retreated successfully with thrombolysis.
Thrombolysis with recombinant streptokinase is efficacious and safe for the treatment of prosthetic heart valve thrombosis. It does not contraindicate surgical treatment if there is no total response, because patient goes to surgery in better hemodynamic conditions with lower risk. Nowadays it can be considered as first-line treatment in all patients with prosthetic heart valve thrombosis regardless of functional class unless specific contraindications exist.
人工心脏瓣膜患者发生瓣膜血栓形成是一种严重的并发症。传统治疗方法是急诊手术,但溶栓提供了一种非侵入性的替代方法。在本文中,我们评估了溶栓治疗人工心脏瓣膜血栓形成的疗效和安全性。
分析了哈瓦那心脏病与心血管外科学研究所6年间诊断为人工瓣膜血栓形成并接受治疗的68例患者的数据。他们接受重组链激酶溶栓治疗,30分钟内输注250,000国际单位,随后以100,000国际单位/小时的速度输注72小时,若血栓在此之前溶解则输注时间缩短。评估基于临床和超声心动图检查结果。
受累部位为二尖瓣(50例)、三尖瓣(9例)和主动脉瓣(9例)。人工瓣膜植入的平均时间为6.8年。临床表现形式主要为心力衰竭(纽约心脏协会心功能分级III - IV级),共64例(94.1%)患者。症状出现至诊断的平均时间间隔为10.6天。58例(85.3%)患者治疗完全有效,4例(5.9%)部分有效,6例(8.8%)治疗失败。重组链激酶的总剂量为5.1×10⁶国际单位,平均输注时间为50小时。观察到2例患者发生严重出血并发症。溶栓期间发生5次栓塞事件。4例患者死亡。11例患者出现再血栓形成;其中10例再次成功接受溶栓治疗。
重组链激酶溶栓治疗人工心脏瓣膜血栓形成有效且安全。若未完全有效,并不妨碍手术治疗,因为患者在血流动力学状况较好、风险较低的情况下接受手术。目前,除非存在特定禁忌证,对于所有人工心脏瓣膜血栓形成患者,无论其心功能分级如何,均可将其视为一线治疗方法。